Mineralys Therapeutics (MLYS) Competitors $13.51 +0.32 (+2.43%) Closing price 08/12/2025 04:00 PM EasternExtended Trading$13.29 -0.22 (-1.63%) As of 08/12/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLYS vs. SWTX, SRRK, MLTX, PTGX, AAPG, HCM, INDV, APLS, MOR, and KYMRShould you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include SpringWorks Therapeutics (SWTX), Scholar Rock (SRRK), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), HUTCHMED (HCM), Indivior (INDV), Apellis Pharmaceuticals (APLS), MorphoSys (MOR), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Mineralys Therapeutics vs. Its Competitors SpringWorks Therapeutics Scholar Rock MoonLake Immunotherapeutics Protagonist Therapeutics Ascentage Pharma Group International HUTCHMED Indivior Apellis Pharmaceuticals MorphoSys Kymera Therapeutics Mineralys Therapeutics (NASDAQ:MLYS) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends. Which has more risk and volatility, MLYS or SWTX? Mineralys Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Which has stronger earnings and valuation, MLYS or SWTX? Mineralys Therapeutics has higher earnings, but lower revenue than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.73-3.62SpringWorks Therapeutics$191.59M18.48-$258.13M-$3.41-13.78 Do analysts prefer MLYS or SWTX? Mineralys Therapeutics currently has a consensus price target of $32.25, suggesting a potential upside of 138.71%. SpringWorks Therapeutics has a consensus price target of $52.57, suggesting a potential upside of 11.88%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Mineralys Therapeutics is more favorable than SpringWorks Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75SpringWorks Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13 Do institutionals and insiders hold more shares of MLYS or SWTX? 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 33.2% of Mineralys Therapeutics shares are owned by company insiders. Comparatively, 7.8% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is MLYS or SWTX more profitable? Mineralys Therapeutics has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -115.60%. SpringWorks Therapeutics' return on equity of -51.10% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -71.15% -65.71% SpringWorks Therapeutics -115.60%-51.10%-43.80% Does the media refer more to MLYS or SWTX? In the previous week, Mineralys Therapeutics had 8 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 0 mentions for SpringWorks Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.43 beat SpringWorks Therapeutics' score of 0.00 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Mineralys Therapeutics Neutral SpringWorks Therapeutics Neutral SummaryMineralys Therapeutics beats SpringWorks Therapeutics on 10 of the 15 factors compared between the two stocks. Get Mineralys Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLYS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLYS vs. The Competition Export to ExcelMetricMineralys TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$859.66M$3.00B$5.49B$9.69BDividend YieldN/A2.29%4.64%4.14%P/E Ratio-3.6219.9630.4025.31Price / SalesN/A359.17448.35103.92Price / CashN/A40.7837.7258.50Price / Book3.527.658.306.01Net Income-$177.81M-$54.75M$3.26B$265.10M7 Day Performance0.37%0.95%1.48%1.39%1 Month Performance-6.76%8.12%3.66%2.43%1 Year Performance14.20%10.97%40.97%24.74% Mineralys Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLYSMineralys Therapeutics2.3465 of 5 stars$13.51+2.4%$32.25+138.7%+19.1%$859.66MN/A-3.6228News CoverageEarnings ReportSWTXSpringWorks TherapeuticsN/A$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230SRRKScholar Rock4.5002 of 5 stars$36.99+1.7%$44.14+19.3%+239.7%$3.45B$33.19M-14.62140Trending NewsEarnings ReportAnalyst RevisionMLTXMoonLake Immunotherapeutics2.2085 of 5 stars$53.32+0.8%$73.14+37.2%+21.1%$3.39BN/A-23.182PTGXProtagonist Therapeutics1.8676 of 5 stars$53.83flat$66.10+22.8%+34.3%$3.34B$434.43M71.77120Earnings ReportAnalyst RevisionAAPGAscentage Pharma Group InternationalN/A$37.60+1.1%N/AN/A$3.25B$134.35M0.00600News CoverageHCMHUTCHMED3.1407 of 5 stars$17.28+0.1%$28.00+62.0%-24.4%$3.01B$630.20M0.001,811Positive NewsAnalyst DowngradeINDVIndivior1.4165 of 5 stars$21.22+0.8%$17.75-16.4%+84.4%$2.90B$1.17B34.231,051APLSApellis Pharmaceuticals4.6414 of 5 stars$24.26+5.7%$36.83+51.8%-33.9%$2.90B$781.37M-13.33770MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730News CoverageKYMRKymera Therapeutics3.0507 of 5 stars$43.66+1.6%$59.11+35.4%-6.2%$2.80B$47.07M-14.08170Trending NewsEarnings Report Related Companies and Tools Related Companies SWTX Competitors SRRK Competitors MLTX Competitors PTGX Competitors AAPG Competitors HCM Competitors INDV Competitors APLS Competitors MOR Competitors KYMR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLYS) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access